KP Tissue, Inc.TSX: KPT

Third Quarter 2026 KP Tissue Financial Statements

· Issued by KP Tissue, Inc.

Summary by 6ix AI

KP Tissue Inc., which holds a 12.0% interest in tissue maker Kruger Products Inc., reported unaudited net income of C$3,100 thousand, or $0.31 per share, for the three months ended September 30, 2026. That compares with C$1,550 thousand, or $0.15 per share, for the same period of 2025.

Key details

  • For the nine months ended September 30, 2026, net income was C$7,722 thousand, or $0.77 per share, compared with C$5,868 thousand, or $0.59 per share, for the nine months ended September 30, 2025.
  • Kruger Products had revenue of C$589,655 thousand and net income attributable to Kruger Products of C$27,708 thousand for the three months ended September 30, 2026.
  • KP Tissue's investment in Kruger Products was carried at C$76,293 thousand on September 30, 2026, compared with C$69,799 thousand on December 31, 2025.
  • On October 15, 2026, KP Tissue paid a dividend of $2.1 million, or $0.21 per common share, and issued 5,582 common shares at $11.80 under its dividend reinvestment plan, through which shareholders can take dividends as new shares.
  • KP Tissue declared a dividend of $2.1 million, or $0.21 per common share, payable on January 15, 2027.

6ix AI wrote this summary from the release below and checked it against the release.

KP TISSUE INC.

UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE 3-MONTH AND 9-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND SEPTEMBER 30, 2025

KP Tissue Inc.

2 Prologis Blvd., Suite 500, Mississauga, Ontario L5W 0G8 https://www.kptissueinc.com

Unaudited Condensed Statements of Financial Position

(tabular amounts are in thousands of Canadian dollars)

‌September 30, 2026

Note $

December 31, 2025

$

Assets Current assets

Dividends receivable

2,107

1,803

Non-current assets

Investment in associate 5

2,107

76,293

1,803

69,799

Total assets

78,400

71,602

Liabilities Current liabilities

Dividends payable 6

2,107

1,803

Total liabilities

Equity

Common shares 6

Contributed surplus Deficit

Accumulated other comprehensive income

2,107

23,194

144,819

(109,511)

17,791

1,803

23,001

144,819

(114,985)

16,964

Total equity

76,293

69,799

Total liabilities and equity

78,400

71,602

Unaudited Condensed Statements of Income and Comprehensive Income For the 3-month and 9-month periods ended September 30, 2026 and September 30, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

‌Note

3-month period ended September 30, 2026

$

3-month

period ended

9-month

period ended

9-month

period ended

September 30, 2025 September 30, 2026

$ $

September 30, 2025

$

Share of income

3,310

1,700

8,359

6,372

Depreciation of fair value increments

(269)

(264)

(808)

(827)

Equity income

3,041

1,436

7,551

5,545

Dilution gain

59

114

171

323

Net income

3,100

1,550

7,722

5,868

Other comprehensive income (loss) net of income tax

expense (recovery) 6

Items that will not be reclassified to net income: Remeasurements of pensions Remeasurements of post-retirement benefits

Items that may be subsequently reclassified to net income:

Cumulative translation adjustment

2,293

441

3,468

537

284

5

301

34

(56)

523

827

(1,227)

Other comprehensive income (loss)

2,521

969

4,596

(656)

Total comprehensive income

5,621

2,519

12,318

5,212

Basic and diluted earnings per share

0.31

0.15

0.77

0.59

Weighted average number of shares outstanding

10,031,675

10,007,057

10,026,643

10,000,087

Unaudited Condensed Statements of Changes in Equity For the 9-month periods ended September 30, 2026 and September 30, 2025

(tabular amounts are in thousands of Canadian dollars, except share amounts)

‌Note

#

Share capital

$

Contributed

surplus Deficit

$ $

Accumulated

other comprehensive

income

$

Total equity

$

As of January 1, 2026

10,015,366

23,001

144,819

(114,985)

16,964

69,799

Issuance of common shares

6

17,021

192

-

-

-

192

Dividends payable

6

-

-

-

(2,107)

-

(2,107)

Dividends paid

-

-

-

(3,909)

-

(3,909)

Fair value adjustment

-

1

-

(1)

-

-

Remeasurement of pensions

-

-

-

3,468

-

3,468

Remeasurement of post-retirement benefits

-

-

-

301

-

301

Cumulative translation adjustment

-

-

-

-

827

827

Net income

-

-

-

7,722

-

7,722

As of September 30, 2026

10,032,387

23,194

144,819

(109,511)

17,791

76,293

Share capital

Contributed

surplus Deficit

$ $

Accumulated

other comprehensive

income

$

Total equity

$

Note

#

$

As of January 1, 2025

9,987,547

22,762

144,819

(116,673)

18,609

69,517

Issuance of common shares

6

20,612

170

-

-

-

170

Dividends payable

6

-

-

-

(1,801)

-

(1,801)

Dividends paid

-

-

-

(3,598)

-

(3,598)

Fair value adjustment

-

2

-

(2)

-

-

Remeasurement of pensions

-

-

-

537

-

537

Remeasurement of post-retirement benefits

-

-

-

34

-

34

Cumulative translation adjustment

-

-

-

-

(1,227)

(1,227)

Net income

-

-

-

5,868

-

5,868

As of September 30, 2025

10,008,159

22,934

144,819

(115,635)

17,382

69,500

Unaudited Condensed Statements of Cash Flows For the 9-month periods ended September 30, 2026 and September 30, 2025

(tabular amounts are in thousands of Canadian dollars)

‌Note

9-month period ended

September 30, 2026

$

9-month period ended

September 30, 2025

$

Cash flows from (used in) operating activities

Net income

7,722

5,868

Items not affecting cash

Equity income

(7,551)

(5,545)

Dilution gain

(171)

(323)

Total items not affecting cash

(7,722)

(5,868)

Net cash from operating activities

-

-

Cash flows from (used in) investing activities

Dividends received, net

6

5,522

5,229

Net cash from investing activities

5,522

5,229

Cash flows from (used in) financing activities

Dividends paid, net

6

(5,522)

(5,229)

Net cash used in financing activities

(5,522)

(5,229)

Increase in cash and cash equivalents during the period

-

-

Cash and cash equivalents - Beginning of period

-

-

Cash and cash equivalents - End of period

-

-

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

  1. GENERAL INFORMATION

    KP Tissue Inc. (KPT or the Corporation) was incorporated by articles of incorporation under the Canadian Business Corporations Act on October 1, 2012. As of September 30, 2026, the Corporation held a 12.0% interest in Kruger Products Inc. (Kruger Products) (December 31, 2025 - 12.1%).

    Kruger Products' principal business is to produce, distribute, market and sell a wide range of disposable tissue products, including bathroom tissue, facial tissue, paper towels and napkins for both the consumer and away-from-home markets in North America. The Corporation's headquarters are located in Mississauga, Ontario, Canada.

  2. BASIS OF PRESENTATION

    ‌These unaudited condensed financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards) applicable to the preparation of interim financial statements, including International Accounting Standards (IAS) 34 - Interim Financial Reporting as issued by the International Accounting Standards Board (IASB), and with interpretations of the International Financial Reporting Committee which the Canadian Accounting Standards Board has approved for incorporation into Part 1 of the CPA Canada Handbook - Accounting. These unaudited condensed financial statements should be read in conjunction with the annual audited financial statements of the Corporation for the year ended December 31, 2025.

    These unaudited condensed financial statements were approved by the board of directors on November 10, 2026.

  3. SUMMARY OF MATERIAL ACCOUNTING POLICIES

    The material accounting policies used in the preparation of these unaudited condensed financial statements were disclosed in the annual audited financial statements of the Corporation for the year ended December 31, 2025 and have been applied to all periods presented.

    ‌Accounting standard implemented effective January 1, 2026

    Amendments to IFRS 9 and IFRS 7 - Amendments to the Classification and Measurement of Financial Instruments

    On May 30, 2024, the IASB issued amendments to IFRS Accounting Standards 9 and IFRS Accounting Standards 7 aimed at improving the classification and measurement of financial instruments. The recent amendments simplify financial reporting by allowing earlier recognition of liabilities settled via electronic payments, clarifying the assessment of cash flows for basic lending arrangements, and refining definitions for non-recourse features and linked instruments. The amendments also introduce more detailed disclosure requirements for fair value changes in equity instruments and mandate reporting of terms that could affect cash flow timings or amounts. The amendments are effective for periods beginning on or after January 1, 2026 and adoption of these amendments did not have a material effect on the Corporation's condensed interim financial statements. For financial liabilities settled in cash using an electronic payment system, the election was applied to deem these financial liabilities to be discharged before the settlement date. The amendments were applied retrospectively, with no restatement of comparative information, in accordance with transition requirements on initial application of IFRS 9.

    (tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

    ‌Accounting standard issued but not yet implemented:

    IFRS 18, Presentation and Disclosure in Financial Statements

    In April 2024, the IASB issued IFRS 18 to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1, impacts the presentation of primary financial statements and notes, mainly the income statement where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. IFRS 18 will require management-defined performance measures to be explained and included in a separate note within the unaudited condensed financial statements. The mandatory effective date would be for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application. The Corporation has substantially completed its assessment of IFRS 18 and does not expect the adoption of the standard to have a material impact on its unaudited condensed statement of income. The adoption of IFRS 18 is not expected to impact the Corporation's reported financial results.

  4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

    The preparation of these unaudited condensed financial statements in conformity with IFRS Accounting Standards requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities in the unaudited condensed financial statements and the disclosure of contingencies at the dates of the unaudited condensed statement of financial position, and the reported amounts of revenues and expenses during the reporting period. On a regular basis and with the information available, management reviews its estimates and judgments, including those related to fair value and the basis of accounting. Actual results could differ from those estimates. When adjustments become necessary, they are reported in earnings in the period in which they occur.

    ‌The estimates and judgement applied by management that most significantly affect the unaudited condensed financial statements are the same as the ones that applied to the annual audited financial statements for the year ended December 31, 2025.

  5. INVESTMENT IN ASSOCIATE

    Changes in the carrying amount of the investment were as follows:

    9-month period ended

    September 30, 2026

    9-month period ended

    September 30, 2025

    $

    $

    Opening balance

    69,799

    69,517

    Increase in investment

    192

    170

    Share of income

    8,359

    6,372

    Depreciation of fair value increments

    (808)

    (827)

    Share of other comprehensive income (loss)

    4,596

    (656)

    Dilution gain

    171

    323

    Dividends

    (6,016)

    (5,399)

    Closing balance

    76,293

    69,500

    (tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

    The following summarizes financial information about the assets, liabilities, revenue and net income of Kruger Products, in which the Corporation holds a 12.0% interest as of September 30, 2026. The financial information was derived from the unaudited condensed financial statements of Kruger Products for the 3-month and 9-month periods ended September 30, 2026. The assets and liabilities disclosed include the fair value adjustments made to the carrying amount of the assets and liabilities of the associate on its acquisition.

    September 30, 2026

    Kruger Products Fair value

    basis of accounting increment

    $ $

    KPT

    basis of accounting

    $

    Current assets

    724,830

    -

    724,830

    Non-current assets

    2,002,388

    285,267

    2,287,655

    Liabilities

    1,942,563

    -

    1,942,563

    Net assets

    784,655

    3-month period ended

    9-month period ended

    September 30, 2026

    September 30, 2026

    $

    $

    Revenue

    Net income attributable to Kruger Products Other comprehensive income

    589,655

    27,708

    21,188

    1,685,193

    69,637

    37,740

    Total comprehensive income attributable to Kruger Products

    48,896

    107,377

    December 31, 2025

    Kruger Products Fair value

    basis of accounting increment

    $ $

    KPT

    basis of accounting

    $

    Current assets

    678,083

    -

    678,083

    Non-current assets

    1,930,621

    291,198

    2,221,819

    Liabilities

    1,902,159

    -

    1,902,159

    Net assets

    706,545

    3-month period ended

    9-month period ended

    September 30, 2025

    September 30, 2025

    $

    $

    Revenue 561,145

    Net income attributable to Kruger Products 14,546

    Other comprehensive income (loss) 7,603

    1,643,335

    52,088

    (3,227)

    Total comprehensive income attributable to Kruger Products 22,149

    48,861

    (tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

    The following shows the reconciliation of KPT's portion of Kruger Products equity to the investment recorded in KPT:

    September 30, 2026

    December 31, 2025

    $

    $

    Kruger Products consolidated equity

    784,655

    706,545

    Add back: Inception value of common shares

    118,562

    118,562

    Less: Equity pertaining to Kruger Inc. and KPGP

    (746,287)

    (675,242)

    Equity pertaining to KPT

    156,930

    149,865

    Investment in associate recorded in KPT

    76,293

    69,799

    Reconciling difference

    80,637

    80,066

    Reconciling items since inception:

    Equity issuance costs

    (11,110)

    (11,110)

    Depreciation of fair value increments

    63,361

    62,553

    Currency translation adjustment in fair value increments

    (2,895)

    (2,829)

    Tax Distribution

    9,181

    9,181

    Gain on exercise of overallotment option

    (375)

    (375)

    Dilution gain

    (5,525)

    (5,354)

    Impairment in investment in associate

    28,000

    28,000

    -

    -

    With respect to KPT's investment in Kruger Products, the liability of KPT for the debts, liabilities and other obligations of Kruger Products is limited to KPT's capital contribution to Kruger Products.

  6. DIVIDENDS

    During the 9-month periods ended September 30, 2026 and September 30, 2025, the Corporation paid quarterly dividends to shareholders. Pursuant to the Corporation Dividend Reinvestment Plan (DRIP), a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing common shares. The proceeds were used to acquire additional shares of Kruger Products. The amount per share, dividends paid, additional common shares issued at the share price, and the gross proceeds were as follows:

    Dividend Payment Date

    Amount per share Dividends paid

    $ $

    Issuance of Share price common shares

    $ #

    2026

    Gross proceeds

    $

    January 15, 2026

    0.18

    1,803

    10.21

    6,971

    71

    April 15, 2026

    0.18

    1,804

    11.09

    5,374

    60

    July 15, 2026

    0.21

    2,107

    13.06

    4,676

    61

    5,714

    17,021

    192

    Dividend Payment Date

    Amount per share Dividends paid

    $ $

    Issuance of Share price common shares

    $ #

    2025

    Gross proceeds

    $

    January 15, 2025

    0.18

    1,798

    8.06

    6,656

    54

    April 15, 2025

    0.18

    1,799

    7.86

    6,713

    54

    July 15, 2025

    0.18

    1,802

    8.87

    7,243

    62

    5,399

    20,612

    170

    (tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

    Subsequent to September 30, 2026, on October 15, 2026, the Corporation paid a dividend of $2.1 million to shareholders at $0.21 per common share. Pursuant to the Corporation DRIP, a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing 5,582 common shares at a price of $11.80.

    Subsequent to September 30, 2026, the Corporation declared a dividend of $2.1 million, payable on January 15, 2027 at $0.21 per common share.

    As a result of the DRIP and Kruger Inc.'s reinvestment of its dividends from Kruger Products in common shares of Kruger Products, a dilution gain of $0.2 million was recorded during the 9-month period ended September 30, 2026 (9-month period ended September 30, 2025 - $0.3 million).

  7. ECONOMIC DEPENDENCE

The Corporation was created to acquire, and its business is limited to holding, a limited equity interest in Kruger Products, which is accounted for as an investment in an associate using the equity method of accounting. As such, the Corporation is economically dependent on Kruger Products and exposed to all the risks associated with the business of Kruger Products, including, but not limited to, liquidity risk.

KP Tissue, Inc. on 6ix

In the deck

Story so far

Earlier from KP Tissue

Later from KP Tissue

All KP Tissue news releases